Framework for interpreting news catalysts in small-cap stocks — bias classification by catalyst type (biotech phases, FDA, buyouts, acquisitions, earnings)

small-cap-news-catalysts-playbook.md

Trading News & Catalysts Guide — Small Caps

Purpose: Framework for interpreting news catalysts in small-cap stocks.

---

1. Why News Matters

In small caps, 80% of strong moves are driven by news catalysts.

When a stock gaps up, there are two scenarios:

1. Pump WITHOUT news (No Catalyst): A move with no fundamental reason. Higher probability of fade.
2. Pump WITH news (Catalyst): Requires reading beyond the headline and confirming with price action.

---

2. Clinical Results (Biotech)

Biotech catalysts are divided into 4 stages. Each stage carries a different bias weight.

Stage	Description	Default Bias
Preclinical	Lab / animal model studies. Far from approval.	Short bias (exception: Alzheimer's, Parkinson's)
Phase 1	First human testing. Focused on safety, not efficacy.	Short bias (exception: Alzheimer's, Parkinson's)
Phase 2	Mid-stage: efficacy + side effects data.	Mixed — can move well but high risk
Phase 3	Final step before requesting FDA approval.	Failure → crash / Success → solid move

Phase 3 — Special Note

• In cancer Phase 3, the bias is often mixed or even long, because the market values any real clinical progress in oncology.

---

3. FDA Catalysts

The FDA regulates drugs and medical devices in the United States. Any FDA communication can move a small cap aggressively.

Catalyst Type	What It Means	Trading Bias
FDA Approval	Final authorization to commercialize the drug.	⚠️ Maximum caution — NOT an easy short.
FDA Designation	Fast Track, Orphan Drug, Breakthrough Therapy, etc. Accelerates development.	Moderate gaps — more tradable.
FDA Positive Opinion	Favorable advisory committee (AdCom) opinion. Not binding.	Pre-approval signal — moderate.
FDA Acceptance	Application accepted for review (NDA, BLA). Administrative step.	Moderate catalyst.

Bias Summary for FDA News

• FDA Approval → Maximum caution (not easy for short bias).
• Designation / Positive Opinion / Acceptance → More predictable, easier to read and trade.

---

4. Buyout vs Acquisition

These are NOT the same. Confusing them can cost you money.

Buyout

• Another company buys the ticker you're trading.
• A fixed price is set → the stock becomes "dead" at that level.
• Rule: BUYOUT = DO NOT TOUCH. Zero volatility, no trade.

Acquisition

• The ticker buys another company.
• Market reaction depends on: price paid, debt added, synergy, and actual value of the acquired business.
• Can create big gaps (up or down).
• Tradable, but requires reading the full news carefully.

---

5. Asset Sale

• The company sells part of its business or properties.
• Looks positive superficially ("they're getting money"), but they're losing long-term value.
• Often creates an initial pop → great for short bias.

---

6. Earnings Reports

Never trust the headline alone. Always check:

• Revenue — top-line growth
• EPS — earnings per share vs expectations
• YoY comparison — year over year trend
• QoQ comparison — quarter over quarter momentum

---

Quick Reference — Bias Decision Framework

Catalyst	Bias Tendency	Tradability
No news pump	Short	High
Preclinical / Phase 1	Short (except Alzheimer's/Parkinson's)	High
Phase 2	Mixed	Medium
Phase 3 (general)	Depends on result	Medium
Phase 3 (cancer)	Mixed / Long	Low-Medium
FDA Approval	Caution — avoid short	Low
FDA Designation	Short-friendly	High
FDA Positive Opinion	Moderate	Medium
FDA Acceptance	Moderate	Medium
Buyout	DO NOT TRADE	None
Acquisition	Depends on details	Medium
Asset Sale	Short bias	High
Earnings	Read the numbers	Medium-High

---

Key Principles

1. Small caps live and die by catalysts.
2. Never trust only the headline — read, compare, and confirm with price action.
3. In biotech: stage + disease relevance + FDA weight determine the bias.
4. FDA Approval = maximum caution for shorts.
5. Buyout ≠ Acquisition — never confuse them.
6. Earnings — always read the actual numbers.